The results (LPI), calculated as the percentage of CD45+ cells with aggregated platelet (CD41+), showed that unactivated MPN (u-MPN) patients had more LPI than unactivated controls (u-CTR), with mean ± SE of 13.01 ± 1.12 and 5.01 ± 0.97 in u-MPN and u-CTR, respectively (P  < 0.05). This evidence concerns the gene PTPRC and myeloproliferative neoplasm.